North Charleston, South Carolina
March 9, 2005

Argolyn Bioscience announced today the addition of a fifth issued patent to its growing intellectual property portfolio.

U.S. Patent Number 6,858,396 titled "Positively charged non-natural amino acids, methods of making and using thereof in peptides" covers the structure and uses of another set of amino acid analogs invented by Dr. Thomas A. Dix and exclusively licensed to Argolyn Bioscience for the optimization of peptide-based pharmaceutical candidates.

"This patent completes the second series of compounds devised by Dr. Dix, and creates a sizeable footprint around the intellectual property that is key to Argolyn's future growth," said Pearce Gilbert, president of Argolyn Bioscience. "Foreign equivalents are still pending, but the success in prosecuting the US cases suggests a good probability that the foreign cases also will issue in due course."

Argolyn Bioscience Inc.

Argolyn Bioscience Inc. is a peptide drug development company headquartered in North Charleston, South Carolina. Argolyn is the exclusive worldwide licensee for a portfolio of patents and patent applications aimed at improving the pharmacology of peptide drug candidates. The company has one product in preclinical development and several other discovery stage pharmaceutical product programs. Argolyn Bioscience continues to seek other opportunities to disseminate the technology either through collaboration or out-licensing.

For more information, contact the company or visit the website at www.argolyn.com.

Contact:

Pearce Gilbert
Argolyn Bioscience Inc.
Tel: (843) 266-0851
Fax: (843) 266-0894
info@argolyn.com